Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions - Concepedia

Concepedia

Publication | Closed Access

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

56

Citations

0

References

2016

Year

Florence Namour, Julie Desrivot, Annegret Van der Aa, Pille Harrison, Chantal Tasset, Gerben van’t Klooster

Drug Metabolism Letters

Abstract

the collective in vivo and in vitro data on drug-metabolizing enzymes and on key drug transporters, support co-administration of filgotinib with commonly used RA drugs to patients without the need for dose adjustments.